Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Extra expenses call for smart tweaks. This intro covers simple ways to adjust your budget to accommodate additional costs.
12,871 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
IBM is quietly reshaping its story with a serious quantum strategy, strong enterprise demand, and a durable dividend....
Kelley Blue Book unveils Kelley Blue Book Homes, a real estate lead platform that pays upfront to access seller leads...
A billionaire places a bold personal bet on a private space company. This article breaks down what that move means fo...
Policy clarity clears the path for road ahead build-to-rent projects, lifting investor confidence. Still, the pace of...
When a biotech deal moves a small cap, it can set the tone for the whole sector. This story explains what happened wi...
ASML dominated the latest quarter with strong results and higher guidance. This article breaks down what that could m...
Missed Sandisk's 580% rally? No worry. You can still ride the AI-driven chip surge with three smart stock picks, clea...
A blockbuster TSMC update is reshaping the AI chip market. Here are three stocks I’m buying after Taiwan’s announceme...
A massive AI spending wave among hyperscalers could redefine markets. Discover why billionaire Bill Ackman is placing...
As the IoT market expands, Synaptics is recalibrating its business to capture devices beyond smartphones. This deep d...
A broad rally in nuclear stocks helped Constellation Energy ride the wave. This piece breaks down the catalysts, what...